September 20, 2017 1:00 PM ET

Biotechnology

Company Overview of Celixir Limited

Company Overview

Celixir Limited, a biotechnology company, discovers, develops, and delivers life-saving and life-altering regenerative medicines to help patients with the greatest medical need. Its products in pipeline include Heartcel, a investigational cardiac regenerative medicine that consists of iMP cells, which are designed to treat patients with ischaemic heart disease–ischaemic cardiomyopathy–undergoing coronary artery bypass graft; Tendoncel, an investigational topical gel that contains platelet lysate capable of regenerating injured tendons near the surface of the skin; and Myocardion progenitor cells for the treatment of patients with mild to moderate heart failure. Celixir Limited was formerly k...

The Maynard Centre

Forest Farm Industrial Estate

Longwood Drive

Cardiff,  CF14 7YT

United Kingdom

Founded in 2009

Key Executives for Celixir Limited

Founder, Chairman and Chief Scientific Officer
Co-Founder and Executive Director
Chief Medical Adviser and Research & Development Director
Medical Director
Compensation as of Fiscal Year 2017.

Celixir Limited Key Developments

Cell Therapy and Daiichi Sankyo Enter Licensing Agreement for Innovative Cardiac-Regenerative Treatment

Cell Therapy (UK) and Daiichi Sankyo (Japan) have entered into a licensing agreement in Japan for innovative cardiac-regenerative treatment Heartcel (allogeneic stem cells), the companies said in a statement. Under the agreement, Cell Therapy will receive a GBP 12.5-million upfront licensing fee and additional milestone payments and royalties, while Daiichi Sankyo will undertake all development, regulatory, and commercial activities for Heartcel in Japan. In addition, Cell Therapy will retain global rights to Heartcel outside of Japan, as well as global manufacturing responsibilities. Treatment with Heartcel involves the Heartcel product injecting modified cells into the patient's heart tissue to repair scarring associated with heart failure, a condition which affects approximately 26 million people globally.

Daiichi Sankyo Company, Limited Signs License Agreement with Cell Therapy Ltd. for Heartcel

Daiichi Sankyo Company, Limited announced the signing of a license agreement with Cell Therapy Ltd. for an exclusive license in Japan to develop and market Heartcel, a immune-modulatory progenitor (iMP) cell therapeutic agent for ischemic heart failure currently in development. Heartcel is an allogeneic iMP cell therapeutic agent created using a new CTL proprietary method. Heartcel is to be injected into the cardiac muscle for expected therapeutic effects in patients suffering from ischemic heart failure. In Japan, Daiichi Sankyo will develop and market Heartcel, while CTL will maintain manufacturing responsibilities for clinical trials and commercialization. Daiichi Sankyo will make a lump-sum payment to CTL on the signing of the agreement, followed by future milestone and sales royalty payments.

Cell Therapy Limited Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016

Cell Therapy Limited Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016. Venue: Hilton Zurich Airport Hotel, 27 Belsize Lane, London | NW3 5AS, United Kingdom. Presentation Date & Speakers: Mar-15-2016, Ajan Reginald, Co-Founder and Executive Director, Mark Beards, Corporate Development Director.

Similar Private Companies By Industry

Company Name Region
Abcellute Ltd. Europe
Abcodia Ltd. Europe
Abeterno Ltd. Europe
Abgentis Limited Europe
Achilles Therapeutics Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Celixir Limited, please visit www.celixir.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.